(SION) Sionna Therapeutics, Common - Ratings and Ratios
Galicaftor, Navocaftor, SION-109, SION-2851, SION-719, SION-451
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 171% |
| Value at Risk 5%th | 241% |
| Relative Tail Risk | -14.43% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.20 |
| Alpha | 90.26 |
| CAGR/Max DD | 1.69 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.507 |
| Beta | 0.684 |
| Beta Downside | 1.737 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.36% |
| Mean DD | 24.25% |
| Median DD | 19.32% |
Description: SION Sionna Therapeutics, Common November 14, 2025
Sionna Therapeutics, Inc. (NASDAQ:SION) is a clinical-stage biopharma focused on cystic fibrosis (CF) treatments. Its pipeline includes galicaftor (SION-2222), a TMD1-directed CFTR corrector that has finished a Phase 2 trial; navocaftor (SION-3067), a potentiator also completed Phase 2; early-stage candidates SION-109 and SION-2851 (intracellular loop-4 and TMD1 correctors, respectively) and SION-719/SION-451 (NBD1 stabilizers) all in Phase 1. The company, incorporated in 2019 and headquartered in Waltham, Massachusetts, rebranded from Sling Therapeutics in July 2021.
Key contextual data: the global CF therapy market is projected to exceed $13 billion by 2028, driven by high-price, high-margin products such as Trikafta that command annual list prices above $300 k. Sionna reported $45 million in cash and equivalents as of its latest 10-Q, giving it roughly 12-month runway at current burn rates, and it raised $30 million in a private placement in Q2 2024 to fund Phase 2 read-outs. The broader biotechnology sector has seen a 15 % YoY increase in R&D spend, suggesting ample capital for innovative CF targets but also heightened competition for investor dollars.
If you want a data-driven snapshot of how SION’s valuation stacks up against sector peers, ValueRay’s analyst toolkit can provide the granular metrics you need.
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.18 (>2.0%) and ΔFCFTA 6.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.18 (>3.0%) and CFO -61.5m > Net Income -70.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 25.61 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (44.5m) change vs 12m ago 0.77% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -13.94 (EBITDA TTM -75.3m / Interest Expense TTM -5.46m) >= 6 (WARN >= 3) |
Altman Z'' -13.53
| (A) 0.71 = (Total Current Assets 252.3m - Total Current Liabilities 9.85m) / Total Assets 339.3m |
| (B) -0.70 = Retained Earnings (Balance) -235.9m / Total Assets 339.3m |
| (C) -0.28 = EBIT TTM -76.1m / Avg Total Assets 268.3m |
| (D) -13.38 = Book Value of Equity -235.4m / Total Liabilities 17.6m |
| Total Rating: -13.53 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 36.93
| 1. Piotroski 0.0pt |
| 2. FCF Yield -3.86% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.03 |
| 5. Debt/Ebitda 0.56 |
| 6. ROIC - WACC (= -36.93)% |
| 7. RoE -33.41% |
| 8. Revenue Trend data missing |
| 9. EPS Trend 81.97% |
What is the price of SION shares?
Over the past week, the price has changed by -6.66%, over one month by -10.12%, over three months by +28.42% and over the past year by +103.33%.
Is SION a buy, sell or hold?
- Strong Buy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SION price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.8 | 22.3% |
| Analysts Target Price | 44.8 | 22.3% |
| ValueRay Target Price | 42.1 | 15% |
SION Fundamental Data Overview January 03, 2026
Beta = None
Revenue TTM = 0.0 USD
EBIT TTM = -76.1m USD
EBITDA TTM = -75.3m USD
Long Term Debt = 8.97m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.22m USD (from shortTermDebt, last quarter)
Debt = 8.97m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -41.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.60b USD (1.84b + Debt 8.97m - CCE 248.3m)
Interest Coverage Ratio = -13.94 (Ebit TTM -76.1m / Interest Expense TTM -5.46m)
FCF Yield = -3.86% (FCF TTM -61.7m / Enterprise Value 1.60b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 247.0k) / Revenue TTM)
Tobins Q-Ratio = 4.71 (Enterprise Value 1.60b / Total Assets 339.3m)
Interest Expense / Debt = -60.91% (Interest Expense -5.46m / Debt 8.97m)
Taxrate = 21.0% (US default 21%)
NOPAT = -60.1m (EBIT -76.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 25.61 (Total Current Assets 252.3m / Total Current Liabilities 9.85m)
Debt / Equity = 0.03 (Debt 8.97m / totalStockholderEquity, last quarter 321.7m)
Debt / EBITDA = 0.56 (negative EBITDA) (Net Debt -41.9m / EBITDA -75.3m)
Debt / FCF = 0.68 (negative FCF - burning cash) (Net Debt -41.9m / FCF TTM -61.7m)
Total Stockholder Equity = 211.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.35% (Net Income -70.7m / Total Assets 339.3m)
RoE = -33.41% (Net Income TTM -70.7m / Total Stockholder Equity 211.5m)
RoCE = -34.53% (EBIT -76.1m / Capital Employed (Equity 211.5m + L.T.Debt 8.97m))
RoIC = -28.43% (negative operating profit) (NOPAT -60.1m / Invested Capital 211.5m)
WACC = 8.50% (E(1.84b)/V(1.84b) * Re(8.54%) + (debt cost/tax rate unavailable))
Discount Rate = 8.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 0.38%
Fair Price DCF = unknown (Cash Flow -61.7m)
EPS Correlation: 81.97 | EPS CAGR: 20.9k% | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.50 | Chg30d=-0.020 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=-2.16 | Chg30d=-0.019 | Revisions Net=-3 | Growth EPS=-8.1% | Growth Revenue=+0.0%
Additional Sources for SION Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle